110P - Uncommon epidermal growth factor receptor mutations in patients with non-small cell lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Matthijs Oyaert
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors M. Oyaert1, I. Demedts2, E. Boone1, J. Van Dorpe3, E. De Laere1, J. Breyne1
  • 1Molecular Diagnostics, AZ Delta Roeselare Menen, 8800 - Roeselare/BE
  • 2Pneumology, AZ Delta Roeselare Menen, 8800 - Roeselare/BE
  • 3Pathology, AZ Delta Roeselare Menen, 8800 - Roeselare/BE


Classic activating mutations in the EGFR tyrosine kinase domain, such as L858R and deletions in exon 19, have been strongly associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with Non-Small Cell Lung Cancer (NSCLC). Other mutations, e.g. T790M, show drug resistance. Detection of EGFR mutations has become an important issue for therapeutic decision-making in NSCLC. The clinical significance of uncommon EGFR mutations, however, remains poorly understood. The present study describes clinical outcomes of 6 patients with uncommon EGFR mutations, receiving TKI.